Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.